St Peter’s Cardiac Unit utilise Siemens technology to achieve excellence

St Peter’s Hospital in Chertsey’s Cardiac Catheterisation Laboratories is being showcased as a centre of excellence, with the help of an Artis zee ceiling-mounted and floor-mounted imaging system from Siemens Healthcare.

The Cardiac Unit is a result of a partnership between InHealth and Ashford and St Peter’s Hospitals NHS Foundation Trust, bringing the Trust’s cardiac diagnostic facilities together under one roof. The unit has been making use of the system’s dose-saving applications that are delivered as standard with the Artis zee.
 
The Cardiac Unit houses two labs; the Artis zee ceiling-mounted system is used to assess the electrical activity and conduction pathways of the heart and the Artis zee floor-mounted system is used to diagnose a range of heart conditions via angiogram procedures. Both labs are set up to undertake interventional procedures such as Coronary Angioplasty and Rotablation.
 
“The installation of a ceiling-mounted and floor-mounted Artis zee shows the combined commitment from InHealth and Ashford and St Peter’s Hospitals NHS Trust to provide patients with the very best care. We have been impressed with the training Siemens Healthcare provided, and its response to any issues encountered during the installation.” states Mimi Parker, Service Manager in the Cardiac Unit at St Peter’s Hospital.
 
Ashford and St Peter’s Medical Director and Cardiologist, Dr David Fluck, states: “This equipment has been very well received by the team who have been very impressed with it and found that the system is easy to use with a great range of functionality. One of our radiographers who had not used a Siemens system before said how comfortable he felt using the Artis zee.”
 
The Artis zee can be flexibly and swiftly positioned around the patient as it has a large flat detector and motorised C-arm. Furthermore, the Artis zee’s streamlined tableside control panel features intuitive syngo® icons, providing the operator with increased functionality. The systems are also equipped with the latest CARE (Combined Applications to Reduce Exposure) features and CLEAR post processing technology, supporting excellent image quality at the desired dose.
 
“We are pleased to be able to support St Peter’s Hospital with state-of-the-art technology that will assist in the visualisation of arteries and chambers of the heart to treat any abnormalities,” states Andreas Hadjiphanis, Regional Sales Manager at Siemens Healthcare. “We have been in regular contact with the hospital to ensure installation and service commencement has been smooth and that swift benefits can be gained by both patients and clinicians.”


A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Related news

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...